Bioventix PLC
LSE:BVXP

Watchlist Manager
Bioventix PLC Logo
Bioventix PLC
LSE:BVXP
Watchlist
Price: 3 200 GBX -3.76% Market Closed
Market Cap: 167m GBX
Have any thoughts about
Bioventix PLC?
Write Note

Bioventix PLC
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bioventix PLC
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Bioventix PLC
LSE:BVXP
Total Current Assets
ÂŁ12m
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
11%
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Total Current Assets
$315.1m
CAGR 3-Years
204%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Total Current Assets
ÂŁ404.9m
CAGR 3-Years
63%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Total Current Assets
$966.2m
CAGR 3-Years
52%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Total Current Assets
ÂŁ528.8m
CAGR 3-Years
51%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Total Current Assets
ÂŁ271.1m
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
5%
No Stocks Found

Bioventix PLC
Glance View

Market Cap
167m GBX
Industry
Biotechnology

Bioventix Plc engages in the development and supply of antibodies. The company is headquartered in Farnham, Surrey and currently employs 17 full-time employees. The company went IPO on 2014-04-29. The principal activity of the Company is the development and supply of antibodies. The firm specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics, such as in automated immunoassays used in blood testing. The firm offers a portfolio of antibodies to customers for both commercial use and research and development (R&D) purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The firm also supplies antibody products and services to multinational clinical diagnostics companies. The firm sells its products through direct sales and through distributors.

BVXP Intrinsic Value
3 026.52 GBX
Overvaluation 5%
Intrinsic Value
Price

See Also

What is Bioventix PLC's Total Current Assets?
Total Current Assets
12m GBP

Based on the financial report for Dec 31, 2023, Bioventix PLC's Total Current Assets amounts to 12m GBP.

What is Bioventix PLC's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
11%

Over the last year, the Total Current Assets growth was 15%. The average annual Total Current Assets growth rates for Bioventix PLC have been 7% over the past three years , 6% over the past five years , and 11% over the past ten years .

Back to Top